Top Stocks Today : IIFL Securities has Buy call on Sun Pharmaceutical Ind L - December 26

IIFL Securities recommends buying Sun Pharmaceutical Industries at the current market price of Rs 1835. They believe that the stock has potential to reach Rs 1875 in the future. Sun Pharmaceutical Industries is a leading Indian pharmaceutical company with a strong presence in the global market. The company has a wide range of products in the areas of branded generics, specialty medicines, and over-the-counter products.

About Sun Pharmaceutical Ind L:

Sun Pharmaceutical Industries Limited (Sun Pharma) is a leading global specialty generic and branded pharmaceutical company headquartered in Mumbai, India. The company offers a wide range of pharmaceutical products, including generic, branded generics, and specialty drugs. It has a presence in over 100 countries and has a global workforce of over 40,000 employees. Sun Pharma is known for its strong product pipeline, research and development capabilities, and commitment to quality. The company's product portfolio includes a wide range of therapies, including cardiovascular, diabetes, neurology, gastroenterology, and oncology. Sun Pharma is listed on the National Stock Exchange of India (NSE) and has a market capitalization of over ₹7 trillion.

52 Week Price Trend:

Sun Pharmaceutical Industries' (SUNPHARMA) current market price (CMP) of Rs 1835 is well below its 52-week high of Rs 1960.35. However, it has recovered significantly from its 52-week low of Rs 1236.05. The stock's current valuation implies a reasonable entry point for investors seeking value in the healthcare sector. The company's strong fundamentals, including a robust product portfolio, a wide geographical presence, and ongoing research and development initiatives, support its long-term growth prospects. Market analysts anticipate a potential upside in SUNPHARMA's stock price, making it an attractive investment option for investors with a medium- to long-term perspective.

Stratzy's MOST Analysis:

SUNPHARMA has been rated AA by Stratzy's MOST framework, which evaluates stocks based on four pillars: Management, Outlook, Safety, and Trend. This rating indicates that SUNPHARMA has low Fundamental Risks, demonstrating strong performance in these key areas. The company's management is highly regarded, its outlook is positive, it exhibits financial safety, and its stock price trend is favorable. Overall, SUNPHARMA is considered a solid investment with a strong fundamental profile.

Company's Fundamentals:

Sun Pharmaceutical Industries (SUNPHARMA) is a pharmaceutical company listed on the National Stock Exchange of India (NSE). Its current stock price is indicative of its valuation in the market. The stock's price-to-earnings (PE) ratio of 39.04 suggests that investors are willing to pay 39.04 times the company's annual earnings for each share they own. The price-to-book (PB) ratio of 6.33 implies that the market value of the company's assets is 6.33 times its book value. Lastly, the dividend yield of 0.74% indicates that SUNPHARMA pays out a portion of its earnings as dividends to its shareholders, providing a return on their investment.

Fundamental and Technical information provided in this blog were last updated on 26 Dec, 2024

Disclaimer: The information and recommendations presented in this section, including any attached reports, are sourced from third-party providers through diverse channels. The views and opinions expressed within these materials belong solely to their respective creators. These views and opinions do not necessarily reflect the position of Stratzy Fintech Pvt Ltd. Stratzy explicitly disclaims any guarantees, express or implied, regarding the accuracy and reliability of the provided content. We strongly advise consulting with a licensed financial advisor before making any investment decisions based on this information. Remember, seeking independent financial advice is crucial.